In the meta-analysis of 3 studies 20,28,32 which compared a GLP-1-based therapy against a comparator, GLP-1-based therapies were found to increase % FMD non-significantly (mean difference [95% CI] in the changes from baseline: 1.65 [0.89, 4.18] %
No other specific grant from any funding agency in the public, commercial or not-for-profit sector was received
Pricing is flat and transparent: semaglutide from $190/month and tirzepatide from $290/month, including your provider visits, dosing, and monitoring
The study findings indicated that semaglutide improved glycemic control with lower insulin requirements in adults with T1D when used with AID
Typically, a provider will want to see a recent comprehensive metabolic panel (CMP) and a hemoglobin A1c (HbA1c) test